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Letters to the Editor 571syndrome due to the PFO and aortic dilation. After its surgical
closure, the patient remained well with no further symptoms.
Platypnea-orthodeoxia syndrome is a clinically striking syndrome of
postural hypoxemia with breathlessness (1). Two factors must coexist
for this syndrome to develop: 1) the anatomical factor may be an
interatrial communication via an atrial septal defect, PFO, or fenes-
trated atrial septal aneurysm; and 2) the functional factor may be
cardiac, such as constrictive pericarditis; pulmonary, such as pulmonary
emphysema, recurrent pulmonary embolism, arteriovenous malforma-
tion, or previous pneumonectomy; abdominal, such as liver cirrhosis; or
vascular, such as an aortic aneurysm or elongation, all of which might
cause a deformity of the atrial septum (2,3). Several causes of RL
shunting have been hypothesized, such as redirection of shunt flow or
a stretch of an interatrial hole that occurs with a postural change and
a decrease in right ventricular compliance accentuating the interatrial
gradient with respiration and the Valsalva maneuver (4). In this case,
the RL shunt was not provoked by a passive postural change on a tilt
table but by sitting, especially during inspiration, and abdominal
Figure 2. Contrast CT and TEE Images Showing the Compression
of the RA by Aortic Dilation
(A) In the coronal reformatted plane, the sinus of Valsalva and ascending aorta
were dilated to 4.2 and 4.0 cm in diameter, respectively, and oriented in a hori-
zontal direction, compressing the interatrial septum into the right atrium (RA)
(arrowheads). (B) In the sagittal plane, the compression of the RA (arrowheads)
and the positional relationship between the inferior vena cava and the patent
foramen ovale (PFO) (arrow) were clearly indicated. These ﬁndings as well as an
increase in venous return to the RA may have accounted for right-to-left shunt-
ing via the PFO. (C) Transesophageal echocardiographic (TEE) imaging con-
ﬁrmed computed tomographic (CT) imaging ﬁndings. Scale bars  2 cm.
Ao  aorta; HV  hepatic vein; LA  left atrium; PA  pulmonary artery.compression. Accordingly, we speculated that the compression of the wight atrium by aortic dilation, the positional relationship between the
nferior vena cava and the PFO, and an increase in venous return to the
ight atrium accounted for RL shunting via the PFO.
Platypnea-orthodeoxia syndrome is recognized as a relatively
ncommon condition and might be overlooked. However, pa-
ients with interatrial communication are not rare. Therefore,
his syndrome should be kept in mind in patients presenting
ith dyspnea with postural hypoxemia.
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For supplementary videos and their legends, please see the online version of
this article.
Superior Doctor at a
Point-of-Care
A Call to Change HF Management
We read with great interest both the paper by Kalogeropoulos et al.
(1) and the accompanying editorial by Abhayaratna (2) regarding
the role of echocardiography and N-terminal pro–B-type natri-
uretic peptide (NT-proBNP) in screening for heart failure (HF).
There is no doubt that standard echocardiography plays a key
role in the management of such individuals. However, the costs of
a standard echocardiographic examination are not negligible and, in
fact, could be prohibitive if it was used as a screening tool in a large
number of asymptomatic patients, especially in the middle- and
low-income countries. In addition, numerous surveys demonstrated
limited access to standard echocardiography even in high-income
countries. For example, in IMPROVEMENT (Improvement pro-
gramme in evaluation and management of heart failure), only 45%
of primary care physicians reported that they would routinely
consider echocardiography in a patient with suspected HF (3).
early the same results were obtained by the recent SHAPE (Study
roup on HF Awareness and Perception in Europe) survey, in
hich 75% of primary care physicians reported that they often or
lways diagnosed HF by signs and symptoms alone, and only 35%
ould arrange for further investigations. According to the SHAPE
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Letters to the Editor572investigators, access to echocardiography was poor in nearly all
countries; only 16% could obtain echocardiograms directly and 34%
via specialists within 1 month (4).
As underscored by Abhayaratna (2), given the growing challenge
to maximize health gains with limited healthcare resources, studies
should be designed with a view to addressing the key question of “at
what cost” should echocardiography be used as a screening tool.
There is an ongoing discussion on what is the most cost-effective
strategy to screen for left ventricular systolic dysfunction (5). Data
from literature and our own experience seem to be strong enough to
consider point-of-care, hand-carried echocardiography as a reliable
HF screening method. We recently demonstrated that simplified
echocardiographic examinations, using a simplified imaging proto-
col, performed by a noncardiologist with basic training in echocar-
diography, yielded significant diagnostic and prognostic informa-
tion in a community (in a cohort of patients with HF and/or HF
risk factors) (6). In the multivariate analysis, both abnormal
point-of-care echocardiogram and elevated NT-proBNP levels
were independent predictors of the adverse outcome. Of interest,
the best cutoff value for NT-proBNP to predict combined endpoint
was 206 pg/ml, which is similar to that obtained by Kalogeropoulos
et al. (190 pg/ml) (1).
One of the tasks of primary care physicians is to “prevent sickness
from clinically manifest HF,” by the early detection of HF risk
factors and asymptomatic left ventricular dysfunction. Point-of-care
hand-carried ultrasound examinations performed by primary care
physicians, using simplified imaging protocols would render them
“superior doctors” and limit the referrals to standard echocardiog-
raphy to those patients in whom “ultrasound stethoscope” screening
was positive or equivocal. Although careful and methodical studies
looking at the reliability, accuracy, and cost-effectiveness of diag-
noses made by caregivers with basic training have yet to be done,
they are important as we are facing a HF epidemic and a wide
application of ultrasound stethoscopes might change the standards
of care and make them more cost-effective.
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We thank Dr. Lipczyn´ska and colleagues for their interest in our work
(1). However, it is crucial to differentiate between the various uses of
chocardiography in heart failure (HF). Our paper focuses on risk
tratification for future clinical (stage C) HF and has implications for
ubclinical heart disease (stage B HF) screening (1). Therefore, our
nferences cannot be extrapolated to clinical HF, where assessment by
chocardiography is a class I indication by most guidelines. The low
ates of echocardiography referral for patients with suspected or con-
rmed HF among primary care physicians (PCPs) cannot be solely
ttributed to cost or limited access as implied. Delayed uptake of
vidence-based practices among PCPs is a key factor. In IMPROVE-
ENT (Improvement programme in evaluation and management of
eart failure) (2), 82% of patients eventually had echocardiography
espite 45% of PCPs recommending it, a discrepancy that is difficult to
xplain by waiting times or workforce distribution by that time (3). In
HAPE (Study Group on HF Awareness and Perception in Europe),
he disparities in HF management between internists, PCPs, and
ardiologists extended to all evidence-based measures, pointing to gaps
n provider education (4).
Echocardiography for risk stratification based on HF risk profile or
creening for stage B HF is a different domain. In our paper, we have
xpressed concerns that screening—as the sole HF prevention strate-
y—is unlikely to have a tangible impact on HF burden, especially
hen limited to detection of left ventricular systolic dysfunction
LVSD). The limitations of LVSD screening are not remediable by
mproving patient selection or, alternatively, by containing the unit cost
f echocardiography; these limitations are rooted in the epidemiology
f HF. Most HF cases are older adults, most of whom have HF with
reserved ejection fraction, which carries mortality and population
ttributable risk of death (5) and cost of care (6) comparable to HF
ith reduced ejection fraction. Screening for LVSD, the primary use of
and-carried ultrasound, would not detect these cases. Therefore, the
ffectiveness of a screening strategy that misses most future cases, and
hat may result in false positives incurring expense and risk of
dditional testing, is dubious.
Screening may be beneficial for the individual patient with a high
re-test probability of potentially treatable findings—although this
ould have to include abnormalities beyond LVSD. From this
erspective, patient selection in combination with unit-cost con-
ainment is worth considering. In this spirit, hand-carried ultra-
ound is an interesting option for individuals with 10% projected
F risk, reserving the full test for those with positive/equivocal
ndings. Finally, the concordance in basic echocardiogram inter-
